Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help [Seeking Alpha]
Geron (NASDAQ:GERN) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights